KANSAS CITY, Kan., Oct. 20, 2022 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical firm using its proprietary Precision Timed Release™ (PTR™) drug supply platform know-how to construct and advance a pipeline of next-generation pharmaceutical merchandise, as we speak introduced that Cingulate Chairman & CEO Shane J. Schaffer will current at the LD Micro Main Event XV investor convention on October 26, 2022.
Conference and presentation particulars are as follows:
| Event: | LD Micro Main Event XV |
| Date: | Wednesday, October 26, 2022 |
| Presentation: | 10:00 a.m. Pacific Time |
| Live stream: | https://me22.mysequire.com/ |
| Location: | Luxe Sunset Boulevard Hotel, Los Angeles |
Management will host particular person investor conferences. To organize a gathering with Cingulate, please contact your convention consultant. Investors might also contact Cingulate investor relations at [email protected] to organize an in-person assembly.
About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical firm using its proprietary PTR™ drug supply platform know-how to construct and advance a pipeline of next-generation pharmaceutical merchandise, designed to enhance the lives of sufferers affected by incessantly recognized circumstances characterised by burdensome day by day dosing regimens and suboptimal remedy outcomes. With an preliminary concentrate on the remedy of neurological problems, Cingulate is figuring out and evaluating extra therapeutic areas the place PTR™ know-how could also be employed to develop future product candidates, together with to deal with anxiousness problems. Cingulate is headquartered in Kansas City. For extra data go to Cingulate.com.
Investor Contact:
Thomas Dalton
Vice President, Investor & Public Relations, Cingulate
[email protected]
913-942-2301
Matt Kreps
Darrow Associates Investor Relations
214-597-8200
[email protected]
